A total cholesterol of 240 on its own tells an underwriter almost nothing. The same number with an HDL of 70 and the same number with an HDL of 30 describe two different risks, and carriers price the difference.
Our high cholesterol page covers how the condition is assessed generally. This one deals with the two questions that decide most files: which number is actually being read, and what happens when you are treated for it.
The ratio, not the total
Most carriers work from the total cholesterol to HDL ratio — total divided by HDL — rather than the total figure alone. It is the standard cardiovascular risk convention, it appears on the lab report the carrier orders, and it is the number that moves a health class.
Two worked examples, using the same total:
- Total 240, HDL 60 → ratio 4.0
- Total 240, HDL 30 → ratio 8.0
The second is a materially worse file than the first, on identical total cholesterol. This is why “my cholesterol is high” is not, by itself, an underwriting problem, and why people with an alarming total figure and good HDL are frequently surprised by their offer.
Carriers set their own acceptable ratio bands, and those bands are not published — the same constraint that applies across the rest of this site and is explained on our how underwriting works page. What is consistent is which number they are looking at.
Treated usually reads better than untreated
This surprises people, and it is the most useful thing on this page.
Being prescribed a statin does not, on its own, produce a rating at most carriers. What underwriters are reading is the current lab result and the evidence that the condition is being managed. A treated ratio of 4.0 is a treated ratio of 4.0. An untreated ratio of 7.5, with a prescription in the pharmacy record that is not being filled, is a different and worse file — because it shows a diagnosed condition and no evidence of control.
The reasoning is the same one that runs through diabetic and hypertensive underwriting: carriers are pricing management, not diagnosis. Someone who sees a doctor, takes what is prescribed and produces improving numbers is a better risk than someone with the same biology and no engagement, and the file shows the difference.
Practical consequence: do not delay an application in order to come off medication. It is a common instinct and it works against you.
Timing, and what a single bad reading does
Cholesterol moves. A reading taken after a bad few months is not permanent, and carriers know this — but they price the reading in front of them.
If your most recent panel is unrepresentative and you have a documented history of better numbers, two things help. Supply the history rather than the latest result alone, so the trend is visible. And if a repeat panel is due soon anyway, it is often worth waiting for it rather than applying on the worst reading you have.
Where a carrier wants more context it will request an Attending Physician’s Statement — a summary from your doctor. That adds weeks. Supplying your own records up front sometimes avoids it.
What sits alongside it
High cholesterol is rarely underwritten in isolation, because it rarely occurs in isolation. The factors that move a cholesterol file further than the lipids do:
- Blood pressure — the combination is weighted more heavily than either alone
- Build — height and weight, which nearly every carrier scores separately
- Smoking — the single largest multiplier available in this category
- Any cardiac event — which moves the file to our heart and stroke page entirely
- Family history — carriers commonly ask about cardiac disease or death in a parent or sibling before age 60, and familial hypercholesterolaemia is assessed differently from diet-driven elevation
Cholesterol with nothing else attached is a mild file. Cholesterol plus hypertension plus a raised build score is where ratings appear.
Which route to apply through
Elevated cholesterol on its own is one of the conditions accelerated underwriting handles best. There is no exam, the decision is fast, and a well-controlled ratio frequently clears the model without any human review.
The catch is that accelerated programs read lab data from other sources, so a poor recent panel can route the application into full underwriting. That is a delay rather than a decline.
Simplified issue is the fallback if the numbers are poor and you want a decision without a blood draw. For most people with treated cholesterol and no cardiac history, it is a more expensive answer to a question that did not need it.
What to do next
Find your most recent lipid panel and work out your ratio — total divided by HDL. That one number tells you more about how an application will go than the total on the top line does.
If the ratio is good, apply through an accelerated program and expect a fast answer. If it is poor, and a repeat panel is due within a couple of months, wait for it. And either way, keep taking what has been prescribed: the file reads better treated than untreated, every time.